1321514-06-0

Basic information

• Product Name: azd4635
• Synonyms: azd4635;6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;1,2,4-Triazin-3-amine, 6-(2-chloro-6-methyl-4-pyridinyl)-5-(4-fluorophenyl)-
• CAS NO: 1321514-06-0
• Molecular Formula: C₁₅H₁₁ClFN₅
• Molecular Weight: 315.7327432
• Mol File: 1321514-06-0.mol

Chemical Properties

• Boiling Point: 491.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.387±0.06 g/cm3(Predicted)
• PKA: 1.75±0.63(Predicted)
• CAS DataBase Reference: azd4635(CAS DataBase Reference)
• NIST Chemistry Reference: azd4635(1321514-06-0)
• EPA Substance Registry System: azd4635(1321514-06-0)

Safety Data

• Hazardous Substances Data: 1321514-06-0(Hazardous Substances Data)

Usage

Uses

AZD4635, is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.

Upstream product

• 697739-22-3 2-chloro-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1321517-59-2 6-bromo-5-(4-fluorophenyl)-1,2,4-triazin-3-amine 
• 107128-47-2 5-(4-fluorophenyl)-1,2,4-triazin-3-amine 
• 447-43-8 1-(4-fluorophenyl)-2,2-dihydroxyethan-1-one 
• 30838-93-8 2-chloro-4,6-dimethyl-pyridine 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 2582-30-1 aminoguanidine bicarbonate 
• 1937-19-5 1-aminoguanidine hydrochloride 

Relevant articles and documents

Synthetic Route Design of AZD4635, an A2AR Antagonist

The AstraZeneca approach to synthetic Route Design is exemplified through our AZD4635 chemical development program. The identification of possible new route concepts is presented, as well as their subsequent prioritization for practical exploration based on project objectives. Selected ideas were tested to demonstrate proof of concept for the bond formation strategy and, where successful, were fed into a decision tool based on key SELECTion principles.

Multikilogram-Scale Preparation of AZD4635 via C-H Borylation and Bromination: The Corrosion of Tantalum by a Bromine/Methanol Mixture

An efficient route to AZD4635 has been developed utilizing the Suzuki-Miyaura reaction of a boronate ester prepared by C-H borylation on a multikilogram scale. Preparation of the cross-coupling partner using bromine/pyridine/methanol has highlighted the incompatibility of this reagent/solvent combination with tantalum, which is commonly used in the construction and repair of standard manufacturing vessels.

1,2,4-TRIAZINE-4-AMINE DERIVATIVES

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.